<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690755</url>
  </required_header>
  <id_info>
    <org_study_id>ENDA-037-04F</org_study_id>
    <nct_id>NCT00690755</nct_id>
  </id_info>
  <brief_title>Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome</brief_title>
  <official_title>Defective Atypical PKC Activation in Diabetes and Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are examining the activation of insulin signaling factors in skeletal
      muscles of human diabetics. The investigators are characterizing the defects in signaling,
      and are examining the effects of anti-diabetic agents and exercise on signaling to glucose
      transport biochemical machinery and whole body glucose disposal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We have provided clear evidence that insulin activation of all three signaling components,
      Viz., IRS-1-dependent PI 3-Kinase, atypical protein kinase C (aPKC) and PKB/Akt is defective
      in diabetic muscle. These defects are best seen when insulin activation is conducted at both
      half-maximal and maximal stimulation. Moreover, whereas previous studies had shown that
      treatment with metformin (Met) alone improves aPKC activation, or that treatment with
      thiazolidinedione (TZD) alone produces increases in activation of IRS-1/PI3K and aPKC when
      evaluated at maximal insulin stimulation, we have recently found that combined treatment with
      Met plus TZD for 6 weeks provokes marked increases in insulin effects on all three signaling
      factors at both half-maximal and maximal insulin stimulation. This work is being prepared for
      submission for publication.

      We have also evaluated the improvement in insulin signaling in diabetic muscle 4 hours after
      acute endurance (one-legged) exercise and found that the responsiveness of aPKC to the lipid
      PI3K-derived activator, PIP3, was improved. Also increased was the activation by insulin of
      IRS-2-dependent PI3K, ERK1/2, and downstream protein synthesis machinery, viz., p70S6 kinase
      and eukaryotic elongation factor eEF2. These effects of exercise would be expected to enhance
      glucose transport and utilization by muscle, and promote protein synthesis, i.e., an anabolic
      response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Alterations in PKC-zeta mRNA in Vastus Lateralis Skeletal Muscles</measure>
    <time_frame>PKC-zeta mRNA levels and aPKC activity in muscle evaluated 40 minutes post-insulin treatment</time_frame>
    <description>All muscle samples obtained by 9/30/07, final date for examination of samples 9/30/08 Muscle dependent ability to diminish blood glucose levels during insulin treatment.</description>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Actual">157</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>type 2 diabetic individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>type 1 diabetic individuals or those with diabetes secondary to pancreatic disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>non-diabetic individuals who are not considered to be overweight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>non-diabetic individuals who are considered to be overweight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <description>non-diabetic and type 2 diabetic individuals who will be subjected to an exercise study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <description>individuals who have or are suspected of having glucose intolerance, including patients who have a history of gestational diabetes and patients who have polycystic ovary syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <description>healthy non-diabetic subjects who will receive one dose of metformin orally 1-2 hours before performing procedures</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Muscle biopsies taken before and after insulin stimulation in euglycemic clamp studies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        type 2 diabetes controlled by diet or oral agents and comparable non-diabetic control
        subjects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable uncomplicated type 2 diabetes

          -  Able to be off oral treatments for 2 months

        Exclusion Criteria:

          -  Diabetic complications related to heart, eye, nerve problems

          -  Renal impairment

          -  Cardiovascular disease

          -  Hepatic disease

          -  Prior history of other disorders or complications caused by diseases

          -  Insulin therapy needed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert V Farese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Office of Research and Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Temofonte N, Sajan MP, Nimal S, Pastoor T, Fumero C, Casaubon L, Powe JL, Standaert ML, Farese RV. Combined thiazolidinedione-metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle. Diabetologia. 2009 Jan;52(1):60-4. doi: 10.1007/s00125-008-1180-z. Epub 2008 Oct 30.</citation>
    <PMID>18972094</PMID>
  </results_reference>
  <results_reference>
    <citation>Beeson M, Sajan MP, Daspet JG, Luna V, Dizon M, Grebenev D, Powe JL, Lucidi S, Miura A, Kanoh Y, Bandyopadhyay G, Standaert ML, Yeko TR, Farese RV. Defective Activation of Protein Kinase C-z in Muscle by Insulin and Phosphatidylinositol-3,4,5,-(PO(4))(3) in Obesity and Polycystic Ovary Syndrome. Metab Syndr Relat Disord. 2004 Spring;2(1):49-56. doi: 10.1089/met.2004.2.49.</citation>
    <PMID>18370676</PMID>
  </results_reference>
  <results_reference>
    <citation>Casaubon L, Sajan MP, Rivas J, Powe JL, Standaert ML, Farese RV. Contrasting insulin dose-dependent defects in activation of atypical protein kinase C and protein kinase B/Akt in muscles of obese diabetic humans. Diabetologia. 2006 Dec;49(12):3000-8. Epub 2006 Oct 7.</citation>
    <PMID>17028898</PMID>
  </results_reference>
  <results_reference>
    <citation>Luna V, Casauban L, Sajan MP, Gomez-Daspet J, Powe JL, Miura A, Rivas J, Standaert ML, Farese RV. Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects. Diabetologia. 2006 Feb;49(2):375-82. Epub 2006 Jan 5.</citation>
    <PMID>16395615</PMID>
  </results_reference>
  <results_reference>
    <citation>Beeson M, Sajan MP, Dizon M, Grebenev D, Gomez-Daspet J, Miura A, Kanoh Y, Powe J, Bandyopadhyay G, Standaert ML, Farese RV. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes. 2003 Aug;52(8):1926-34.</citation>
    <PMID>12882907</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <results_first_submitted>May 22, 2015</results_first_submitted>
  <results_first_submitted_qc>April 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2016</results_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared, as data is presented in the published paper as a mean plus or minus SEM.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Type 2 diabetic</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>Type 1 diabetic</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>Control (non-diabetic)</description>
        </group>
        <group group_id="P4">
          <title>Group 4</title>
          <description>Non-diabetic overweight</description>
        </group>
        <group group_id="P5">
          <title>Group 5</title>
          <description>Non-diabetic and Type 2 diabetic</description>
        </group>
        <group group_id="P6">
          <title>Group 6</title>
          <description>Impaired glucose tolerance (IGT)</description>
        </group>
        <group group_id="P7">
          <title>Group 7</title>
          <description>Non-diabetic treated with Metformin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="97"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28">Patient recruitment ended on 12/31/2010</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Type 2 diabetic</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Type 1 Diabetic</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>Control (non-diabetic)</description>
        </group>
        <group group_id="B4">
          <title>Group 4</title>
          <description>Non-Diabetic Overweight</description>
        </group>
        <group group_id="B5">
          <title>Group 5</title>
          <description>Non-Diabetic and Type 2 Diabetic subjected to exercise study</description>
        </group>
        <group group_id="B6">
          <title>Group 6</title>
          <description>Impaired glucose tolerance (IGT)</description>
        </group>
        <group group_id="B7">
          <title>Group 7</title>
          <description>Non-Diabetic treated with Metformin</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="0"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="0"/>
            <count group_id="B8" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="1"/>
                    <measurement group_id="B3" value="47" spread="3"/>
                    <measurement group_id="B4" value="51" spread="3"/>
                    <measurement group_id="B6" value="43" spread="3"/>
                    <measurement group_id="B8" value="47" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B8" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B8" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B8" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Alterations in PKC-zeta mRNA in Vastus Lateralis Skeletal Muscles</title>
        <description>All muscle samples obtained by 9/30/07, final date for examination of samples 9/30/08 Muscle dependent ability to diminish blood glucose levels during insulin treatment.</description>
        <time_frame>PKC-zeta mRNA levels and aPKC activity in muscle evaluated 40 minutes post-insulin treatment</time_frame>
        <population>PKC-zeta mRNA and aPKC activity in vastus lateralis skeletal muscle was measured by analysis of gene expression levels of PKC and measuring them in relative amounts in comparison to control subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Type 2 diabetic</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Type 1 diabetic</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Control (non-diabetic)</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Non-diabetic overweight</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>Non-diabetic and Type 2 diabetic</description>
          </group>
          <group group_id="O6">
            <title>Group 6</title>
            <description>Impaired glucose tolerance (IGT)</description>
          </group>
          <group group_id="O7">
            <title>Group 7</title>
            <description>Non-diabetic treated with Metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Alterations in PKC-zeta mRNA in Vastus Lateralis Skeletal Muscles</title>
          <description>All muscle samples obtained by 9/30/07, final date for examination of samples 9/30/08 Muscle dependent ability to diminish blood glucose levels during insulin treatment.</description>
          <population>PKC-zeta mRNA and aPKC activity in vastus lateralis skeletal muscle was measured by analysis of gene expression levels of PKC and measuring them in relative amounts in comparison to control subjects.</population>
          <units>arbitrary units/ng rRNA</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.088"/>
                    <measurement group_id="O3" value="3.58" spread="0.179"/>
                    <measurement group_id="O4" value="2.14" spread="0.107"/>
                    <measurement group_id="O6" value="2.22" spread="0.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Diabetics</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Type 1 diabetes</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>Control (non-diabetic)</description>
        </group>
        <group group_id="E4">
          <title>Group 4</title>
          <description>Non-diabetic overweight</description>
        </group>
        <group group_id="E5">
          <title>Group 5</title>
          <description>Non-diabetic and Type 2 diabetic</description>
        </group>
        <group group_id="E6">
          <title>Group 6</title>
          <description>Impaired glucose tolerance (IGT)</description>
        </group>
        <group group_id="E7">
          <title>Group 7</title>
          <description>Non-diabetic treated with Metformin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Syncopal event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>As the study progressed, it was determined that there was not scientific merit to the Groups 2, 5 or 7. These groups were, therefore, not pursued.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Farese, MD</name_or_title>
      <organization>James A. Haley VA Research Department</organization>
      <phone>813-972-2000</phone>
      <email>Robert.Farese@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

